Finding and bring new pharmaceuticals to market is both long and expensive. n those early years, the screening to find interesting or novel drugs can be automated, so the expense of dead ends is not too high. But as you move out of the lab into those Phase One and Two trials, the cost of backing a dead end goes way up; you have to spend a great deal of money on clinical trials that involve patients, physicians, and coordinators. The large pharmaceutical companies often “outsource” these early phases of drug development by purchasing promising start-ups, who have already entered Phase One and Two studies, when risk and cost are more aligned. Good for Big Pharma, and at some point for us, but not so good for those start-ups where funding can become problematic.
One of the areas that suffer this “valley of death” dearth of funding is Usher1b - a rare, truly genetic disorder that results in the loss of vision for about 200,000 patients annually. One RP patient, a Washington lobbyist, involved in financing has provided a ground-up solution, Bio-Bonds.